Canadian who visited 16 U.S. locations had measles, Seattle health officials say
The local public health office in Seattle is warning residents there of a confirmed case of measles in a Canadian resident who spent time in the region two weeks ago.
Article content
Article content
The notice from Public Health — Seattle and King County says the person spent time in King and Snohomish counties between April 30 and May 3 while infectious, and adds that their vaccine status is unknown. (The Seattle metropolitan area overlaps with three counties — King, Snohomish and Pierce.)
Article content
'In addition to traveling through Seattle-Tacoma International Airport, the person visited multiple public locations in Renton, Bellevue, Seattle, Everett and Woodinville while contagious with measles, but before being diagnosed with measles,' the notice says.
Article content
Article content
The notice then lists 16 locations alongside dates and times, including a winery, two fitness centres and a local hotel as 'locations of potential exposure.'
Article content
'These times include the estimated period when the individual was at the location and two hours after,' the notice says. 'Measles virus can remain in the air for up to two hours after someone infectious with measles leaves the area. Anyone who was at the … locations during the times listed could have been exposed to measles.'
The health authority says the case is not connected to any previous local measles cases. Public Health — Seattle and King County says it has responded to two other measles cases this year among people who traveled through King County but were not Washington state residents, adding there have been five cases of measles in Washington state residents this year.
Article content
Article content
Measles was declared eliminated in Canada in 1998, and in the United States two years later. However, falling vaccination rates have caused outbreaks to occur in Canada, Mexico, and the U.S., with cross-border transmission as well.
Article content
Article content
Last month, the New York State Department of Health went so far as to issue a travel advisory for those who may be crossing the border, especially anyone travelling to Ontario.
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
23 minutes ago
- National Post
AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies
Article content AUSTIN, Texas — ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a leader in AI-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonstrating that its artificial intelligence (AI)-designed GLP-1 receptor agonist (GLP-1RA) peptide sequences achieve comparable or superior receptor activation to Semaglutide, a benchmark GLP-1 therapy and one of the most commercially successful drugs in the world. The in vitro analysis was conducted by an independent third party, further strengthening the objectivity and reliability of the findings. Article content The results validate the power of IPA's LENSai™ platform and its proprietary HYFT™ technology, which enables first-principles-based in silico peptide discovery and optimization. Five rationally engineered peptide sequences—AI-optimized for improved stability and peptidase resistance—were tested against benchmark GLP-1 analogs in receptor activation assays. Two lead candidates outperformed or matched Semaglutide under controlled assay conditions. Article content Crucially, the sequences were not discovered by chance. They were designed using HYFT-derived intrinsic biological patterns—mathematical representations of functional relationships in biology—making this approach highly reproducible and generalizable to other drug targets. Article content With GLP-1 therapies representing one of the fastest-growing segments in the global pharmaceutical market, these results demonstrate that AI can now generate not only predictive but functionally validated peptide drugs, paving the way for rapid expansion into adjacent therapeutic areas using the same HYFT-driven approach. Article content 'This is not a one-off success,' said Dr. Jennifer Bath, CEO of ImmunoPrecise. 'We've demonstrated a scalable, first-principles mechanism to design potent, stable, and biologically active peptide therapeutics. HYFT-guided design unlocks repeatable workflows for other validated targets—whether in cardiometabolic disease, oncology, or infectious disease. It represents a foundational shift in how therapeutics are discovered. The same LENSai-driven approach has already transformed our vaccine and antibody discovery programs, and we are now applying that rinse-and-repeat methodology to metabolic diseases—starting with GLP-1.' Article content IPA is now considering two complementary preclinical paths for its lead GLP-1 candidates: Article content Injectable delivery studies, including pharmacokinetic profiling and efficacy validation in animal models. Non-invasive delivery strategies, including formulation work for transdermal patches and exploratory evaluation of nucleic acid-based delivery, designed to enhance durability, patient compliance, and ease of administration. Article content The sequences were also engineered for compatibility with next-generation expression systems, including nucleic acid-based vectors, which support scalable expression in both traditional and emerging human-relevant models, aligning with evolving regulatory interest in more predictive, flexible, and efficient therapeutic development approaches. Article content The significance of this breakthrough extends far beyond GLP-1. The same AI framework and HYFT-driven approach that generated these potent peptide drugs can now be applied to other high-value therapeutic targets—quickly, efficiently, and with built-in biological relevance. Article content This announcement follows IPA's recent success with AI-designed dengue virus vaccine candidates, reinforcing the broad applicability of its technology across both infectious and non-infectious diseases. Article content About ImmunoPrecise Antibodies Ltd. Article content ImmunoPrecise (NASDAQ: IPA) is a global leader in AI-powered biotherapeutic discovery and development. Its proprietary HYFT™ technology and LENSai™ platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. IPA partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models. Article content Forward-Looking Statements Article content This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' or similar expressions, or statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. These statements include, but are not limited to, those related to the anticipated benefits, scalability, translatability, adoption, and broader application of the LENSai™ and HYFT® platforms; the advancement and regulatory acceptance of AI-native drug discovery methods; the continued development and potential preclinical or clinical progression of IPA's AI-designed GLP-1 peptide program; the feasibility of next-generation delivery strategies; and the Company's ongoing ability to maintain scientific, regulatory, and commercial momentum in this and related therapeutic areas. Article content Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. Such factors include, but are not limited to, scientific or technological developments, changes in regulatory requirements or acceptance of AI-designed therapeutics, competitive or market dynamics, intellectual property protection and enforcement, risks related to preclinical or clinical validation, integration or operational risks, and changes in economic or business conditions. Article content Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company's SEDAR+ profile at and EDGAR profile at Should any of these risks materialize, actual results could vary significantly from those currently anticipated. Article content Article content Article content Article content Article content Article content
Globe and Mail
an hour ago
- Globe and Mail
Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright 6 th Annual Neuro Perspectives Conference, taking place June 16-17, 2025. Mr. Drysdale's fireside chat will be available on demand beginning on Monday, June 16, 2025, at 7:00 a.m. ET. To listen to the event, please click here to access the webcast. The archived webcast will also be available on the Company's investor relations website on the Events & Presentations page. About Cybin Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram.
CBC
3 hours ago
- CBC
Statistics Canada researchers in Sudbury, as part of national health survey
These Statistics Canada researchers are gathering health data across the country 1 hour ago Duration 1:43 Outside a hockey arena in the Copper Cliff neighbourhood of Sudbury, Ont., there's a group of three interconnected trailers with the Statistics Canada logo blazoned at the top. Since 2007, Canada's national statistical agency has partnered with Health Canada and the Public Health Agency of Canada on the Canadian Health Measures Survey. Over a two-year cycle, researchers visit 16 cities across Canada where they collect data about people's health. Kelsey Wolfenden, the site manager for the survey's temporary examination centre, said it's the first time the survey team has come to the northern Ontario city. Over the course of two weeks, she said researchers expect to meet with around 400 randomly chosen Sudburians – based on Census results – to gather some information about their health. "The first half is a home interview where a Statistics Canada interviewer would come to your household and ask you a bunch of questions about your lifestyle, your diet, things like that," Wolfenden said. At the examination centre they take measurements – such as height, weight and blood pressure. Researchers also collect a blood and urine sample from each participant. There's a small lab on the site that splits the samples and then sends them to labs around the country for further analysis. "The results, they're used as baseline data for policyholders or stakeholders to better understand health trends across Canada," Wolfenden said. For their trouble, each participant receives $150. Wolfenden said she and her team are travelling to a different city every six weeks. "We just finished in Brockville, Ontario, last week and we're doing Sudbury for six weeks," she said. "Then afterwards we'll head to Edmonton, Alberta, for six weeks."
